Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Acromegaly: unravelling a complex disease

D J O'Halloran¹, S M Shalet

¹Department of Endocrinology, Christie Hospital NHS Trust, Manchester, UK.

Growth Regulation

|September 1, 1995

Summary

Acromegaly, a growth hormone disorder, often stems from pituitary tumors. Effective treatment requires endocrinologist supervision and may involve surgery, radiation, or medication like octreotide to manage hormone levels and improve patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Extensive expertise in endocrinology: UK stance on adult GH replacement: the economist vs the endocrinologist.

European journal of endocrinology·2013

Same author

Gastric pacing for diabetic gastroparesis--does it work?

Irish medical journal·2011

Same author

Long-term safety of growth hormone replacement after CNS irradiation.

The Journal of clinical endocrinology and metabolism·2011

Same author

With commentary.

Archives of disease in childhood·2010

Same author

The value of IGF1 estimation in adults with GH deficiency.

European journal of endocrinology·2009

Same author

Failure of antibody response to polysaccharide antigen in treated panhypopituitary adults.

Clinical and experimental immunology·2009

Area of Science:

Endocrinology
Molecular Biology
Oncology

Background:

Acromegaly is a rare endocrine disorder caused by excess growth hormone (GH), typically due to a pituitary macroadenoma.
This condition significantly increases patient morbidity and mortality.
While oncogenic mutations are implicated in less than 50% of cases, the etiology of remaining cases is speculative.

Purpose of the Study:

To review the current understanding of acromegaly, including its causes, diagnosis, and treatment.
To highlight the importance of biochemical cure criteria and monitoring disease activity.
To discuss the efficacy and challenges of various treatment modalities.

Main Methods:

Review of epidemiological evidence and molecular biological studies.
Analysis of biochemical cure criteria based on GH and IGF-1 levels.
Discussion of treatment outcomes for surgery, pituitary irradiation, and medical therapies.

Main Results:

Biochemical cure is defined by mean GH levels ≤ 5 mU/l, correlating with normalized IGF-1.
Treatment success depends on adenoma size and pretreatment GH hypersecretion.
Octreotide is effective in controlling GH hypersecretion, with a long-acting preparation anticipated.

Conclusions:

A combination of therapies is often necessary for satisfactory control of acromegaly.
Careful monitoring for treatment-induced GH deficiency is crucial due to potential cardiovascular mortality risks.
Management requires dedicated endocrinologist supervision tailored to individual patient needs.

Related Experiment Videos